Introduction : Several studies have investigated gender differences in patients with Lewy Body Dementia (LBD), however, whether the observed differences are associated with demographic and pharmacological factors is not fully understood. The current study tested the hypothesis that specific demographic or pharmacological factors may contribute to the observed gender difference. Methods : A 5‐year data collected from a regional registry from 608 LBD patients including 332 men and 276 women were analyzed. Factors associated with men and women patients with LBD were determined using the logistic regression model. Multicollinearity was evaluated using variance inflation factors (VIFs), with values greater than five suggestive of multicollinearity Results : The results indicate that Caucasian men (94.3% vs 83.3%) were more likely to present with LBD. In the adjusted analysis, increasing age (OR = 1.042, 95% CI, 1.025‐ 1.058, P ˂ 0.001) was more likely to be associated with women with LBD, while olanzapine (OR = 2.871, 95% CI, 1.902‐4.334, P˂ 0.001), buspirone (OR = 2.388, 95% CI, 1.527‐3.735, P˂ 0.001), escitalopram (OR = 1.444, 95% CI, 1.079‐1.932, P = 0.014) and tobacco use (OR = 1.424, 95% CI, 1.075‐1.887, P = 0.014) were associated with men with LBD Conclusions : More men presented with LBD compared to women. Our findings reveal specific demographic and pharmacological factors that contribute to gender differences among LBD patients.

Introduction : The role that specific clinical factors play in contributing to gender differences in Alzheimer’s patients with mild cognitive impairment (MCI) is not yet fully understood. In this study, we tested the hypothesis that pharmacological, demographic, and risk factors may contribute to gender difference in Alzheimer’s patients with MCI. Methods : Methods Data collected for 5 years was analyzed using a retrospective data analytical approach on 33,064 Alzheimer patients, including 13,569 men and 19,495 women that presented with MCI. Receiver operating characteristic (ROC) curve analysis and multivariate regression models were used to identify specific factors that contribute to gender differences in MCI patients. Results : Results Our records indicate that women that presented with MCI were more likely to be taking Buspirone (OR = 0.767, 95% CI, 0.683‐0.861, P<0.001) while men within this population were more likely to be taking Galantamine (OR = 0.559, 95% CI, 0.382‐0.818, P<0.001). ETOH use was associated with MCI in both men (OR = 0.696, 95% CI, 0.638‐0.760, P<0.001) and women with Alzheimer’s Dementia (OR = 0.484, 95% CI, 0.442‐0.529, P<0.001). Conclusions : Conclusion Our findings reveal gender differences in men and women that presented with MCI. Management strategies should consider identified factors to provide better care for Alzheimer patients with MCI.

Introduction : Gender differences in dementia patients and Parkinson’s Disease have been investigated extensively; however, factors that contribute to gender differences in Parkinson’s Disease with Dementia patients (PDD) is not fully understood. In this study, we tested the hypothesis that specific, demographic, and pharmacological factors may be associated with men and women patients with PDD, and contribute to gender differences. Methods : Data collected for 5 years from 7594 PDD patients was analyzed using univariate analysis to determine different factors associated with men or women with PDD. Multicollinearity interactions between independent variables in the model were examined using variance inflation factors Results : Overall, 55.22% of the PDD patients were men while 44.77% were women. In the adjusted analysis, Aripiprazole (OR = 0.581, 95% CI, 0.302‐1.118, P = 0.104), ETOH (OR = 0.371, 95% CI, 0.260‐0.531, P<0.001) African American (0.249, 95% CI, 0.088‐0.703, P = 0.009) with PD were more likely to be men. The use of Aripiprazole (OR = 0.195, 95% CI, 0.06‐0.631, P = 0.006), Escitalopram (OR = 0.651, 95% CI, 0.468‐0.906, P = 0.011), and Tobacco (OR = 0.620, 95% CI, 0.444‐0.866, P = 0.005) were associated with women. Conclusions : This study showed that women presented fewer cases of PDD than men. The current study reveals gender differences in PDD patients associated with specific demographic and pharmacological factors

Introduction : Gender differences in dementia patients have been investigated extensively, however, demographic, risk, and pharmacological factors associated with gender differences in dementia patients associated with Lewy Body Dementia(LBD) and Parkinson’s disease with dementia (PDD) are not fully understood. We tested the hypothesis that specific factors may contribute to the observed gender differences in LBD and PDD patients. Methods : A 5‐year retrospective data analytical study was conducted using 4526 men and 3676 women collected from a regional hospital database. We performed logistic regression analysis to determine factors associated with gender differences in LBD and PDD patients. Multicollinearity and significant interactions between independent variables in the model were examined using variance inflation factors, while a Cox & Snell classification was applied to check the model fitness. Results : In the adjusted analysis, African‐American men (AAM) (OR = 0.249, 95% CI, 0.088‐0.703, P = 0.009) were more likely to present with PDD, while women with increasing age (OR = 1.042, 95% CI, 1.025‐1.058, P<0.002) were more likely to present with LBD. Escitalopram was associated with LBD in men (OR = 1.444, 95% CI, 1.079‐1.932, P = 0.014) and PDD in women (OR = 0.651, 95% CI, 0.468‐0.906, P = 0.011). Conclusions : Our findings revealed gender differences in LBD and PDD. More men presented with. PDD based on race, while women presented with LBD more based on age.